Allos dumps drug program after Phase III failure

Allos Therapeutics says that a late-stage trial of Efaproxyn failed to demonstrate significantly increased survival rates for women whose breast cancer had spread to the brain. Women receiving the drug along with radiation therapy lived 8.5 months compared to 7.5 months for women receiving radiation therapy alone. None of the secondary endpoints were achieved, either. As a result, the company says it is shuttering the development program for Efaproxyn and shifting its focus to PDX, a mid-stage therapy designed to treat blood cancer.

- check out the AP report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.